Could a Risk-adapted Approach Support Shared Decision-making Regarding Eligibility for Adjuvant Pembrolizumab for Patients with Clear Cell Renal Cell Carcinoma at High Risk of Recurrence? A Multicentre Cohort Study by Riccardo Campi et al. Full article: buff.ly/4brlqhm

FREE fulltext paper link below: When I started performing radical cystectomies, I always struggled with how to stop and restart anticoagulation perioperatively. 🙄 😮 I then asked myself why this is such a common clinical scenario. I realized that many cystectomy patients

Could a risk-adapted approach support shared decision-making regarding eligibility for adjuvant pembrolizumab for patients with clear cell #RCC at high risk of recurrence? #BeyondTheAbstract with Riccardo Campi on UroToday > bit.ly/3zDHiZG

A brief summary of YAUIstanbul2024 f who could not attend meeting Hope to meet in Istanbul in near future! Juan Gómez Rivas Riccardo Campi Giorgio I. Russo 🩺 Amelia Pietropaolo Beatriz Bañuelos Nadir Osman T. Emre Sener M.İrfan Dönmez EAU Young Academics EAU-YAU Renal Cancer Working Group YAU ENDOUROLOGY EAU_YAUPaedsUrol

Outstanding piece, a must-read! Thank you for these insights Rahul Tendulkar, MD ascopubs.org/doi/10.1200/OP…

Is it safe to implant a #PenileProsthesis in a solid organ #transplant recipient? A systematic review 👉 nature.com/articles/s4144… Angelo Territo Mario Belmonte Andrea Cocci Eduard Ruiz Castañe Fabio Castiglione Guglielmo Mantica Alberto Piana M.İrfan Dönmez Francesco Esperto Giorgio I. Russo 🩺

urotoday.com/recent-abstrac… via UroToday.com

Read our European Urology Oncology editorial “Functional Outcomes of #Stereotactic #Ablative #Radiotherapy: There Is Room for Improvement” referred to the recently published article by the #IROCK #consortium. Nice to collaborate with Laura Bukavina and Giulio Francolini #SABR #SBRT

🚨 New format coming your way! 🚨 We’re excited to introduce the YAU Renal Cancer Spotlight on Minerva Urology and Nephrology ! YAU members will #explore #hot #topics in renal cancer, providing expert insights in an #editorial #format. 🧬 Stay up-to-date with the latest research and

Could a risk-adapted approach support shared decision-making regarding eligibility for adjuvant pembrolizumab for patients with clear cell #RCC at high risk of recurrence? #BeyondTheAbstract with Riccardo Campi on UroToday > bit.ly/3zDHiZG

As I prepare to embark on the next chapter of my European Association of Urology (EAU) journey, I want to take a moment to express my gratitude to EAU Young Academics I have been filled with remarkable experiences, and I am immensely grateful for the support, collaboration, and friendship collected through the

August Issue: Assessing Functional Outcomes of Partial Versus #RadicalNephrectomy for T1b-T2 #RenalMasses : Results from a Multi-institutional Collaboration Paolo Dell'Oglio Carlo Andrea Bravi Zine-Eddine Khene Riccardo Campi rdcu.be/dRnkC Syed A. Ahmad

From the August Issue of AnnalsSurgOncology : Assessing Functional Outcomes of Partial Versus Radical Nephrectomy for T1b-T2 Renal Masses: Results from a Multi-institutional Collaboration #kidneydisease Paolo Dell'Oglio Carlo Andrea Bravi Zine-Eddine Khene Riccardo Campi rdcu.be/dRnkC

#YAU_RenalCancerSpotlight No. 1 Inferior #vena #cava #thrombectomy: Do you think #minimally #invasive surgery will become the #standard? 📖Read our comment on Minerva Urology and Nephrology 🔗Link: pubmed.ncbi.nlm.nih.gov/39051896/ 👥 Savio Domenico Pandolfo Michele Marchioni Riccardo Campi Daniele Amparore

Just in The Lancet Oncology 👉Zr-girentuximab PET–CT is highly accurate for detecting ccRCC #kidneycancer (like PSMA-PET in prostate ca) Congrats, Brian Brian Shuch, MD et al, on these practice-impacting data. Open access👉tinyurl.com/4cwkm8u5 Michael Morris OncoAlert UroToday.com

Congrats to Brian Rini, MD and team! This important study sheds light on the sequential use of agents in RCC. Beyond mPFS, do we need new endpoints? 🧐 #ESMO24 @oncoalert ESMO - Eur. Oncology #cancer #oncology Toni Choueiri, MD Evandro de Azambuja, MD, PhD Andres Cervantes FabriceAndre Emre Yekedüz Neeraj Agarwal, MD, FASCO

First-ever neoadjuvant IO trial shows OS benefit in MIBC! Durvalumab + Chemo improved EFS and OS in muscle-invasive bladder cancer. Significant step forward in #BladderCancer treatment! Tom Powles Uromigos #ESMO24 @oncoalert ESMO - Eur. Oncology #cancer #oncology Toni Choueiri, MD

Seconda edizione del Master in Uro-Oncologia dell’Ud'A ! 🎓 Discutiamo il carcinoma della prostata a 360 gradi, con docenti e discenti eccezionali. Un’occasione di confronto e crescita! 🔝 Grazie a Paolo Dell'Oglio e Riccardo Campi 🙏. Società Italiana di Urologia #UroOncologia #Master

Grazie a te Michele Marchioni, Prof. Schips & team per la bellissima esperienza e per l’ospitalità. Master unico in Italia e davvero all’avanguardia. Bellissima opportunità!

Could a risk-adapted approach support shared decision-making regarding eligibility for adjuvant pembrolizumab for patients with clear cell #RCC at high risk of recurrence? Author commentary with Riccardo Campi on UroToday > bit.ly/3zDHiZG